Zimmer Biomet Holdings, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Zimmer Biomet Holdings, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Tangible Assets Ratio: Of every $100 the company owns, $36 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles. Less tangible than 91% of Healthcare companies in United States.
- Cash Cushion Ratio: Debt, after subtracting cash, equals 37% of its market value (net debt). Lower than 90% of Healthcare companies in United States.
- Cash Locked Ratio: For every $100 of sales, $45 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $45 tied up three years earlier. More money tied up than 87% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
$181Over the last 3 years, every $100 of reported profit came with $181 of operating cash.
Higher than 67% of Healthcare companies in United States.
Self-Funding Ratio
4.6×Over the last 3 years its own operating cash covered its investment spending (capex) 4.6 times.
Higher than 85% of Healthcare companies in United States.
Cash Locked Ratio
$45For every $100 of sales, $45 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $45 tied up three years earlier.
More money tied up than 87% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
3/3 · 1/3Sales grew in 3 of the last 3 years; profit grew in 1 of 3.
Steadier than 69% of Healthcare companies in United States.
Growth Efficiency Ratio
$37Sales grew 19% in 3 years; of every extra $100 of sales, $37 became extra profit.
Higher than 62% of Healthcare companies in United States.
Asset Productivity Ratio
+19% / +10%In 3 years sales changed by +19% while total assets changed by +10%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
2.9×Debt due within a year is covered 2.9 times by its yearly operating cash.
Higher than 77% of Healthcare companies in United States.
Cash Cushion Ratio
−37%Debt, after subtracting cash, equals 37% of its market value (net debt).
Lower than 90% of Healthcare companies in United States.
Tangible Assets Ratio
36%Of every $100 the company owns, $36 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 91% of Healthcare companies in United States.
Tangible Net Worth Ratio
NegativeGoodwill and other intangibles are larger than its whole net worth, so its tangible net worth is negative.
Less tangible than 78% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Zimmer Biomet Holdings, Inc. owes $0.45 for every $1 it owns. Net profit fell 22% in the year to Dec 2025, and grew 45% a year on average over 3 years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
24.0Investors pay $24.0 for every $1 of Zimmer Biomet Holdings, Inc.'s yearly profit, lower than 56% of Healthcare companies in United States.
P/B ratio
1.49The share price is 1.49 times Zimmer Biomet Holdings, Inc.'s book value per share, lower than 67% of Healthcare companies in United States.
Market cap
$18.8 BThe total market value of all of Zimmer Biomet Holdings, Inc.'s shares at today's price (share price × number of shares), larger than 93% of Healthcare companies in United States. PosiCap size class: Tito Cap.
Net worth (book value)
$12.6 BWhat Zimmer Biomet Holdings, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$66.18Net worth divided by the number of shares. The share price of $98.81 is 1.5 times this, which is the P/B above.
Return on equity (ROE)
6.4%Zimmer Biomet Holdings, Inc. earned 6.4% on its shareholders' money over the last year, higher than 80% of Healthcare companies in United States.
Owes vs Owns
0.45×Zimmer Biomet Holdings, Inc. owes $0.45 for every $1 it owns (low), higher than 52% of Healthcare companies in United States.
Dividend yield
1.01%Zimmer Biomet Holdings, Inc. pays 1.01% of its share price as dividends a year, lower than 54% of dividend-paying Healthcare companies in United States.
Revenue growth
+7%Revenue rose 7% in the year to Dec 2025, and grew 6% a year on average over 3 years.
Profit growth
-22%Net profit fell 22% in the year to Dec 2025, and grew 45% a year on average over 3 years.
Profit margin
8.6%Zimmer Biomet Holdings, Inc. keeps $9 of every $100 of revenue as net profit.
Cash quality
2.4×Cash from Zimmer Biomet Holdings, Inc.'s business was 2.4× its reported profit in the year to Dec 2025 — its profit turned into cash.
Interest cover
4.6×Zimmer Biomet Holdings, Inc.'s operating profit covered its interest costs 4.6 times in the year to Dec 2025.
Cash vs debt
Net debtZimmer Biomet Holdings, Inc. had $6.9 B more debt than cash (net debt) at Dec 2025.
Questions
What is Zimmer Biomet Holdings, Inc.'s P/E ratio?
Investors pay $24.0 for every $1 of Zimmer Biomet Holdings, Inc.'s yearly profit, lower than 56% of Healthcare companies in United States.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Zimmer Biomet Holdings, Inc.: $18.8 B ÷ $12.6 B (30 Jun 2026) = 1.5.
What is Zimmer Biomet Holdings, Inc.'s return on equity?
Zimmer Biomet Holdings, Inc. earned 6.4% on its shareholders' money over the last year, higher than 80% of Healthcare companies in United States.
How much does Zimmer Biomet Holdings, Inc. owe compared with what it owns?
Zimmer Biomet Holdings, Inc. owes $0.45 for every $1 it owns (low), higher than 52% of Healthcare companies in United States.
Does Zimmer Biomet Holdings, Inc. pay a dividend?
Yes. Zimmer Biomet Holdings, Inc. pays 1.01% of its share price as dividends a year, lower than 54% of dividend-paying Healthcare companies in United States.
Is Zimmer Biomet Holdings, Inc.'s revenue growing?
Revenue rose 7% in the year to Dec 2025, and grew 6% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.